Misplaced Pages

Flunitrazepam

Clinical data
Pronunciation	/ˌfluːnɪˈtræzɪpæm/
Trade names	Rohypnol
Other names	roofies, floonies
Pregnancy category	AU: C
Addiction liability	High
Routes of administration	Oral
Drug class	Benzodiazepine
ATC code	N05CD03 (WHO)
Legal status
Legal status	AU: S8 (Controlled drug) BR: Class B1 (Psychoactive drugs) CA: Schedule I DE: Anlage III (Special prescription form required) UK: Class C US: Schedule IV (Schedule I trafficking penalties, however) UN: Psychotropic Schedule III SE: Förteckning II
Pharmacokinetic data
Bioavailability	64–77% (by mouth) 50% (suppository)
Metabolism	Liver
Metabolites	7-aminoflunitrazepam, desmethylflunitrazepam and 3-hydroxydesmethylflunitrazepam
Elimination half-life	18–26 hours
Excretion	Kidney
Identifiers
IUPAC name 5-(2-fluorophenyl)-1-methyl-7-nitro-1H-benzodiazepin-2(3H)-one
CAS Number	1622-62-4
PubChem CID	3380
IUPHAR/BPS	4193
DrugBank	DB01544
ChemSpider	3263
UNII	620X0222FQ
KEGG	D01230
ChEBI	CHEBI:31622
ChEMBL	ChEMBL13280
CompTox Dashboard (EPA)	DTXSID7023065
ECHA InfoCard	100.015.089
Chemical and physical data
Formula	C16H12FN3O3
Molar mass	313.288 g·mol
3D model (JSmol)	Interactive image
Melting point	170–172 °C (338–342 °F)
SMILES CN1C(=O)CN=C(c2ccccc2F)c2cc((=O))ccc21
InChI InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3 Key:PPTYJKAXVCCBDU-UHFFFAOYSA-N
(verify)

Flunitrazepam, sold under the brand name Rohypnol among others, is a benzodiazepine used to treat severe insomnia and assist with anesthesia. As with other hypnotics, flunitrazepam has been advised to be prescribed only for short-term use or by those with chronic insomnia on an occasional basis.

It was patented in 1962 and came into medical use in 1974. Flunitrazepam, nicknamed "roofies" or "floonies", is widely known for its use as a date rape drug.

Use

In countries where this drug is used, it is used for treatment of severe cases of sleeping problems, and in some countries as a preanesthetic agent. These were also the uses for which it was originally studied.

It has also been administered as a concurrent dose for patients that are taking ketamine. Rohypnol lowers the side effects of the anesthetic (ketamine), resulting in less confusion in awakening states, less negative influence on pulse rate, and fewer fluctuations in blood pressure.

Adverse effects

Adverse effects of flunitrazepam include dependency, both physical and psychological; reduced sleep quality resulting in somnolence; and overdose, resulting in excessive sedation, impairment of balance and speech, respiratory depression or coma, and possibly death. Because of the latter, flunitrazepam is commonly used in suicide among the elderly. When used in late pregnancy, it might cause hypotonia of the fetus.

Dependence

Flunitrazepam, as with other benzodiazepines, can lead to drug dependence. Discontinuation may result in benzodiazepine withdrawal syndrome, characterised by seizures, psychosis, insomnia, and anxiety. Rebound insomnia, worse than baseline insomnia, typically occurs after discontinuation of flunitrazepam even from short-term single nightly dose therapy.

Paradoxical effects

Flunitrazepam may cause a paradoxical reaction in some individuals, including anxiety, aggressiveness, agitation, confusion, disinhibition, loss of impulse control, talkativeness, violent behavior, and even convulsions. Paradoxical adverse effects may even lead to criminal behaviour.

Hypotonia

Benzodiazepines such as flunitrazepam are lipophilic and rapidly penetrate membranes and, therefore, rapidly cross over into the placenta with significant uptake of the drug. Use of benzodiazepines including flunitrazepam in late pregnancy, especially high doses, may result in hypotonia, also known as floppy baby syndrome.

Other

Flunitrazepam impairs cognitive functions. This may appear as lack of concentration, confusion and anterograde amnesia—the inability to create memories while under the influence. It can be described as a hangover-like effect which can persist to the next day. It also impairs psychomotor functions similar to other benzodiazepines and nonbenzodiazepine hypnotic drugs; falls and hip fractures were frequently reported. The combination with alcohol increases these impairments. Partial, but incomplete tolerance develops to these impairments.

Other adverse effects include:

• Slurred speech
• Gastrointestinal disturbances, lasting 12 or more hours
• Vomiting
• Respiratory depression in higher doses

Special precautions

Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, in alcohol- or drug-dependent individuals, and in individuals with comorbid psychiatric disorders.

Impairment of driving skills with a resultant increased risk of road traffic accidents is probably the most important adverse effect. This side-effect is not unique to flunitrazepam but also occurs with other hypnotic drugs. Flunitrazepam seems to have a particularly high risk of road traffic accidents compared to other hypnotic drugs. Extreme caution should be exercised by drivers after taking flunitrazepam.

Interactions

The use of flunitrazepam in combination with alcoholic beverages synergizes the adverse effects, and can lead to toxicity and death.

Overdose

Flunitrazepam is a drug that is frequently involved in drug intoxication, including overdose. Overdose of flunitrazepam may result in excessive sedation, or impairment of balance or speech. This may progress in severe overdoses to respiratory depression or coma and possibly death. The risk of overdose is increased if flunitrazepam is taken in combination with CNS depressants such as ethanol (alcohol) and opioids. Flunitrazepam overdose responds to the GABA_A receptor antagonist flumazenil, which thus can be used as a treatment.

Detection

As of 2016, blood tests can identify flunitrazepam at concentrations of as low as 4 nanograms per millilitre; the elimination half life of the drug is 4–12 hours. For urine samples, metabolites can be identified for 60 hours to 28 days, depending on the dose and analytical method used. Hair and saliva can also be analyzed; hair is useful when a long time has transpired since ingestion, and saliva for workplace drug tests.

Flunitrazepam can be measured in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients, provide evidence in an impaired driving arrest, or assist in a medicolegal death investigation. Blood or plasma flunitrazepam concentrations are usually in a range of 5–20 μg/L in persons receiving the drug therapeutically as a nighttime hypnotic, 10–50 μg/L in those arrested for impaired driving and 100–1000 μg/L in victims of acute fatal overdosage. Urine is often the preferred specimen for routine substance use monitoring purposes. The presence of 7-aminoflunitrazepam, a pharmacologically active metabolite and in vitro degradation product, is useful for confirmation of flunitrazepam ingestion. In postmortem specimens, the parent drug may have been entirely degraded over time to 7-aminoflunitrazepam. Other metabolites include desmethylflunitrazepam and 3-hydroxydesmethylflunitrazepam.

Pharmacology

The main pharmacological effects of flunitrazepam are the enhancement of GABA, an inhibitory neurotransmitter, at various GABA receptors. All benzodiazepines work by enhancing the effect of GABA receptors, which, when active, allow chloride ions to enter the neuron. Negative ions such as chloride inhibit the ability of neurons to fire. It is this stimulation of GABA receptors which is responsible for the depressant effects of benzodiazepines. Flunitrazepam shows high affinity for the α-5 subunit of the GABA-A receptor, which causes some of its unique side effects, such as amnesia.

While 80% of flunitrazepam that is taken orally is absorbed, bioavailability in suppository form is closer to 50%.

Flunitrazepam has a long half-life of 18–26 hours, which means that flunitrazepam's effects after nighttime administration persist throughout the next day. This is due to the production of active metabolites. These metabolites further increase the duration of drug action compared to benzodiazepines that produce nonactive metabolites.

Flunitrazepam is lipophilic and is metabolised by the liver via oxidative pathways. The enzyme CYP3A4 is the main enzyme in its phase 1 metabolism in human liver microsomes.

Chemistry

Flunitrazepam is classed as a nitro-benzodiazepine. It is the fluorinated N-methyl derivative of nitrazepam. Other nitro-benzodiazepines include nitrazepam (the parent compound), nimetazepam (methylamino derivative) and clonazepam (2ʹ-chlorinated derivative).

Flunitrazepam has a melting point of around 170 degrees Celsius.

History

Flunitrazepam was discovered at Roche as part of the benzodiazepine work led by Leo Sternbach; the patent application was filed in 1960 and it was first marketed in 1972.

Due to use of the drug for date rape and recreation, in 1998 Roche modified the formulation to give lower doses, make it less soluble, and add a blue dye for easier detection in drinks. It was never marketed in the United States, and by 2016 had been withdrawn from the markets in Spain, France, Norway, Germany, and the United Kingdom.

Society and culture

Recreational and illegal uses

Recreational use

A 1989 article in the European Journal of Clinical Pharmacology reports that benzodiazepines accounted for 52% of prescription forgeries in Sweden, suggesting that benzodiazepines were a major prescription drug class of abuse. Nitrazepam accounted for 13% of forged prescriptions, and accounted for 44% of forgeries specifically for benzodiazepines while flunitrazepam, diazepam, and oxazepam accounted for the majority of the rest of benzodiazepine forgeries. Prescription forgeries for other benzodiazepines marketed in Sweden (alprazolam, clonazepam, lorazepam, clobazam, and bromazepam) were negligible. When calculated in relation to utilization, the narcotic analgesics codeine, pentazocine, and ketobemidone were at the top of the list for the highest number of overall prescription forgeries, suggesting a higher abuse potential of these drugs. In neighboring Finland, temazepam accounts for roughly 40–50% benzodiazepine prescription forgeries annually, while flunitrazepam accounts for approximately ~15% of benzodiazepine prescription forgeries.

Flunitrazepam and other sedative hypnotic drugs are detected frequently in cases of people suspected of driving under the influence of drugs. Other benzodiazepines and nonbenzodiazepines (anxiolytic or hypnotic) such as zolpidem and zopiclone (as well as cyclopyrrolones, imidazopyridines, and pyrazolopyrimidines) are also found in high numbers of suspected drugged drivers. Many drivers have blood levels far exceeding the therapeutic dose range, suggesting a high degree of potential for addiction for benzodiazepines and similar drugs.

Suicide

In studies in Sweden, flunitrazepam was the second most common drug used in suicides, being found in about 16% of cases. In a retrospective Swedish study of 1,587 deaths, in 159 cases benzodiazepines were found. In suicides when benzodiazepines were implicated, the benzodiazepines flunitrazepam and nitrazepam occurred in significantly higher concentrations compared to natural deaths. Of the 159 deaths where any benzodiazepines were found, 4 deaths were caused by benzodiazepines alone (in the other 155 cases, benzodiazepines were combined with something else). One conclusion of the study was that flunitrazepam and nitrazepam might be more toxic than other benzodiazepines available in the Swedish market.

Drug-facilitated sexual assault

Flunitrazepam is known to induce anterograde amnesia in sufficient doses; individuals are unable to remember certain events that they experienced while under the influence of the drug, which complicates investigations. This effect could be particularly dangerous if flunitrazepam is used to aid in the commission of sexual assault; victims may be unable to clearly recall the assault, the assailant, or the events surrounding the assault.

While use of flunitrazepam in sexual assault has been prominent in the media, as of 2015 it appears to be fairly rare, and use of alcohol and other benzodiazepine drugs in date rape appears to be a larger but underreported problem.

In a 2001 study, the benzodiazepines midazolam and temazepam were the two most common benzodiazepines utilized for date rape.

Drug-facilitated robbery

In the United Kingdom, the use of flunitrazepam and other "date rape" drugs have also been connected to stealing from sedated victims. An activist quoted by a British newspaper estimated that up to 2,000 individuals are robbed each year after being spiked with powerful sedatives, making drug-assisted robbery a more commonly reported problem than drug-assisted rape.

Regional use

Flunitrazepam is a Schedule III drug under the international Convention on Psychotropic Substances of 1971.

• In Australia, as of 2013 the drug was authorized for prescribing for severe cases of insomnia but was restricted as a Schedule 8 medicine.
• In France, as of 2016 flunitrazepam was not marketed.
• In Germany, as of 2016 flunitrazepam is an Anlage III Betäubungsmittel (controlled substance which is allowed to be marketed and prescribed by physicians under specific provisions) and is available on a special narcotic drug prescription as the Rohypnol 1 mg film-coated tablets and several generic preparations (November 2016).
• In Ireland, flunitrazepam is a Schedule 3 controlled substance with strict restrictions.
• In Japan, flunitrazepam is marketed by Japanese pharmaceutical company Chugai under the trade name Rohypnol and is indicated for the treatment of insomnia as well as used for preanesthetic medication.
• In Mexico, Rohypnol is legally available.
• In Norway, on January 1, 2003, flunitrazepam was moved up one level in the schedule of controlled drugs and, on August 1, 2004, the manufacturer Roche removed Rohypnol from the market there altogether.
• In South Africa, Rohypnol is classified as a Schedule 6 drug. It is available by prescription only, and restricted to 1 mg doses.

• In Iceland, flunitrazepam is a controlled substance available from Mylan. It is prescribed for severe insomnia and is sometimes used before surgery to induce a calm, relaxed state of mind for the patient.
• In Sweden, flunitrazepam is a List II drug (substances with medicinal uses) under the Narcotics Control Act (1968). It was previously available from Mylan, but has been removed from the market in January 2020.
• In the United Kingdom, flunitrazepam is not licensed for medical use and is a controlled drug under Schedule 3 and Class C.
• In the United States, the drug has not been approved by the Food and Drug Administration and is considered to be an illegal drug; as of 2016 it is Schedule IV. 21 U.S.C. § 841 and 21 U.S.C. § 952 provide for punishment for the importation and distribution of up to 20 years in prison and a fine; possession is punishable by three years and a fine. Travelers travelling into the United States are limited to a 30-day supply. The drug must be declared to US Customs upon arrival. If a valid prescription cannot be produced, the drug may be subject to Customs search and seizure, and the traveler may face criminal charges or deportation.

Names

Flunitrazepam is marketed under many brand names in the countries where it is legal. It also has many street names, including "roofie" and "ruffie". It is also known as Circles, Forget Me Pill, La Rocha, Lunch Money Drug, Mexican Valium, Pingus, R2, and Roach 2.

References

1. Ries RK (2009). Principles of addiction medicine (4 ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 106. ISBN 978-0-7817-7477-2. Archived from the original on September 8, 2017.
2. Anvisa (March 31, 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published April 4, 2023). Archived from the original on August 3, 2023. Retrieved August 16, 2023.
3. ^ "International brands for Flunitrazepam". Drugs.com. Retrieved April 13, 2016.
4. ^ "Prescribing of Benzodiazepines Alprazolam and Flunitrazepam" (PDF). Pharmaceutical Services Branch. New South Wales Health. November 2013. Archived (PDF) from the original on June 23, 2014.
5. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 53X. ISBN 9783527607495.
6. Schwartz RH, Milteer R, LeBeau MA (June 2000). "Drug-facilitated sexual assault ('date rape')". Southern Medical Journal. 93 (6): 558–561. doi:10.1097/00007611-200093060-00002. PMID 10881768.
7. Gautam L, Sharratt SD, Cole MD (February 19, 2014). "Drug facilitated sexual assault: detection and stability of benzodiazepines in spiked drinks using gas chromatography-mass spectrometry". PLOS ONE. 9 (2): e89031. Bibcode:2014PLoSO...989031G. doi:10.1371/journal.pone.0089031. PMC 3929633. PMID 24586489.
8. ^ "Kusuri-no-Shiori Drug Information Sheet". RAD-AR Council, Japan. October 2015. Archived from the original on March 3, 2016. Retrieved June 13, 2016.
9. Mattila MA, Larni HM (November 1980). "Flunitrazepam: a review of its pharmacological properties and therapeutic use". Drugs. 20 (5): 353–374. doi:10.2165/00003495-198020050-00002. PMID 6108205. S2CID 25151953.
10. Freuchen I, Ostergaard J, Kühl JB, Mikkelsen BO (1976). "Reduction of psychotomimetic side effects of Ketalar (ketamine) by Rohypnol (flunitrazepam). A randomized, double-blind trial". Acta Anaesthesiologica Scandinavica. 20 (2): 97–103. doi:10.1111/j.1399-6576.1976.tb05015.x. PMID 7095. S2CID 46172276.
11. Carlsten A, Waern M, Holmgren P, Allebeck P (2003). "The role of benzodiazepines in elderly suicides". Scandinavian Journal of Public Health. 31 (3). SAGE Publications: 224–228. doi:10.1080/14034940210167966. PMID 12850977. S2CID 24102880.
12. ^ "Flunitrazepam (Rohypnol)". Center for Substance Abuse Research. University of Maryland. October 29, 2013. Archived from the original on January 9, 2016.
13. Kales A, Scharf MB, Kales JD, Soldatos CR (April 1979). "Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines". JAMA. 241 (16): 1692–1695. doi:10.1001/jama.241.16.1692. PMID 430730.
14. Bramness JG, Skurtveit S, Mørland J (June 2006). "Flunitrazepam: psychomotor impairment, agitation and paradoxical reactions". Forensic Science International. 159 (2–3): 83–91. doi:10.1016/j.forsciint.2005.06.009. PMID 16087304.
15. Kanto JH (May 1982). "Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations". Drugs. 23 (5): 354–380. doi:10.2165/00003495-198223050-00002. PMID 6124415. S2CID 27014006.
16. ^ Vermeeren A (2004). "Residual effects of hypnotics: epidemiology and clinical implications". CNS Drugs. 18 (5): 297–328. doi:10.2165/00023210-200418050-00003. PMID 15089115. S2CID 25592318.
17. Mets MA, Volkerts ER, Olivier B, Verster JC (August 2010). "Effect of hypnotic drugs on body balance and standing steadiness". Sleep Medicine Reviews. 14 (4): 259–267. doi:10.1016/j.smrv.2009.10.008. PMID 20171127.
18. Authier N, Balayssac D, Sautereau M, Zangarelli A, Courty P, Somogyi AA, et al. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Annales Pharmaceutiques Françaises. 67 (6): 408–413. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
19. Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Mørland J (December 2008). "Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam". Sleep Medicine. 9 (8): 818–822. doi:10.1016/j.sleep.2007.11.011. hdl:10852/34650. PMID 18226959.
20. ^ UK Dept. of Transport. July 2014. "Guidance for healthcare professionals on drug driving" (PDF). The Department for Transport. London. 2014.
21. ^ "Benzodiazepines drug profile". European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). January 8, 2015.
22. Zevzikovas A, Kiliuviene G, Ivanauskas L, Dirse V (2002). "". Medicina. 38 (3): 316–320. PMID 12474705.
23. Jonasson B, Saldeen T (March 2002). "Citalopram in fatal poisoning cases". Forensic Science International. 126 (1): 1–6. doi:10.1016/S0379-0738(01)00632-6. PMID 11955823.
24. ^ Kiss B, Bodoki E, Pop A, Loghin F (2016). "Chapter 48: Assays for Flunitrazepam". In Preedy VR (ed.). Neuropathology of drug addictions and substance misuse. Volume 2, Stimulants, club and dissociative drugs, hallucinogens, steroids, inhalants, and international aspects. London: Academic Press. p. 513. ISBN 978-0-12-800375-6.
25. Jones AW, Holmgren A, Kugelberg FC (April 2007). "Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results". Therapeutic Drug Monitoring. 29 (2): 248–60. doi:10.1097/FTD.0b013e31803d3c04. PMID 17417081. S2CID 25511804.
26. Robertson MD, Drummer OH (January 1998). "Stability of nitrobenzodiazepines in postmortem blood". Journal of Forensic Sciences. 43 (1): 5–8. doi:10.1520/JFS16081J. PMID 9456517.
27. Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 633–635.
28. ^ Santos, Enrique (October 13, 2022). "Flunitrazepam (Rohypnol) Fact Sheet & Harm Reduction Guide". Tripsitter. Retrieved November 15, 2023.
29. Cano JP, Soliva M, Hartmann D, Ziegler WH, Amrein R (1977). "Bioavailability from various galenic formulations of flunitrazepam". Arzneimittel-Forschung. 27 (12): 2383–2388. PMID 23801. rohypnol.
30. Griffin CE, Kaye AM, Bueno FR, Kaye AD (2014). "Benzodiazepine pharmacology and central nervous system-mediated effects". The Ochsner Journal. 13 (2): 214–223. PMC 3684331. PMID 23789008.
31. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ (February 2001). "CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam". Drug Metabolism and Disposition. 29 (2): 133–140. PMID 11159802.
32. Robertson MD, Drummer OH (May 1995). "Postmortem drug metabolism by bacteria". Journal of Forensic Sciences. 40 (3): 382–386. doi:10.1520/JFS13791J. PMID 7782744.
33. Sternbach, L.; et al. (May 1, 1963). "Quinazolines and 1,4-Benzodiazepines. X.1 Nitro-Substituted 5-Phenyl-1,4-benzodiazepine Derivatives2". Journal of Medical Chemistry. 6 (3): 261–265. doi:10.1021/jm00339a010. PMID 14185980. Retrieved November 15, 2023.
34. Alapi EM, Fischer J (2006). "Table of Selected Analogue Classes". In Fische J, Ganellin CR (eds.). Analogue-Based Drug Discovery. Weinheim: Wiley-VCH. p. 537. ISBN 978-3-527-60749-5.
35. Bryan J (September 2009). "Landmark drugs: The discovery of benzodiazepines and the adverse publicity that followed". The Pharmaceutical Journal. 283: 305. Archived from the original on November 20, 2015.
36. Bergman U, Dahl-Puustinen ML (November 1989). "Use of prescription forgeries in a drug abuse surveillance network". European Journal of Clinical Pharmacology. 36 (6): 621–623. doi:10.1007/BF00637747. PMID 2776820. S2CID 19770310.
37. "Classification of controlled drugs". EMCDDA. Retrieved June 30, 2022.
38. Jones AW, Holmgren A, Kugelberg FC (April 2007). "Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results". Therapeutic Drug Monitoring. 29 (2): 248–260. doi:10.1097/FTD.0b013e31803d3c04. PMID 17417081. S2CID 25511804.
39. Jonasson B, Jonasson U, Saldeen T (January 2000). "Among fatal poisonings dextropropoxyphene predominates in younger people, antidepressants in the middle aged and sedatives in the elderly". Journal of Forensic Sciences. 45 (1): 7–10. doi:10.1520/JFS14633J. PMID 10641912.
40. Ericsson HR, Holmgren P, Jakobsson SW, Lafolie P, De Rees B (November 1993). "". Läkartidningen. 90 (45): 3954–3957. PMID 8231567.
41. Drummer OH, Syrjanen ML, Cordner SM (September 1993). "Deaths involving the benzodiazepine flunitrazepam". The American Journal of Forensic Medicine and Pathology. 14 (3): 238–243. doi:10.1097/00000433-199309000-00012. PMID 8311057. S2CID 28937806.
42. Liljesson S (June 3, 1999). "Bankrånare stärkte sig med Rohypnol?". DrugNews. Archived from the original on September 29, 2007. Retrieved May 19, 2006.
43. "Mijailovic var påverkad av våldsdrog". Expressen.
44. El-Sohly MA, Lee LF, Holzhauer LB, Salamone SJ (2001). "Analysis of Urine Samples in Cases of Alleged Sexual Assault". Benzodiazepines and GHB. Forensic Science and Medicine. Humana Press. pp. 127–144. doi:10.1007/978-1-59259-109-1 (inactive November 1, 2024). ISBN 1-59259-109-4.{{cite book}}: CS1 maint: DOI inactive as of November 2024 (link)
45. Thompson T (December 19, 2004). "'Rape drug' used to rob thousands". The Guardian. London. Retrieved May 2, 2010.
46. "List of Psychotropic Substances under International Control" (PDF). Green List (26th ed.). International Narcotics Control Board. 2015. Archived from the original (PDF) on July 13, 2017.
47. "Authorisation to Supply or Prescribe Drugs of Addiction: Flunitrazepam". Statutory Medical Notifications. Department of Health, Government of Western Australia. August 13, 2004. Archived from the original on August 28, 2006. Retrieved March 13, 2006.
48. "Flunitrazepam - Anwendung, Wirkung, Nebenwirkungen". Gelbe Liste. Vidal MMI Germany GmbH.
49. "S.I. No. 342/1993 — Misuse of Drugs (Amendment) Regulations". Irish Statute Book, Statutory Instruments. 1993.
50. "What is Rohypnol?". 12 South Recovery. May 27, 2019. Retrieved January 24, 2021.
51. Bramness JG, Skurtveit S, Furu K, Engeland A, Sakshaug S, Rønning M (February 2006). "". Tidsskrift for den Norske Laegeforening. 126 (5): 589–590. PMID 16505866.
52. "Rohypnol". Drug Wars – About Drugs. October 11, 2006.
53. "Flunitrazepam Mylan". Lyfja - Lifið heil (in Icelandic). Retrieved February 27, 2020.
54. "Flunitrazepam" (in Swedish). Sweden: Medical Products Agency. Retrieved February 17, 2022.
55. "Substans". Farmaceutiska Specialiteter i Sverige (FASS) Allmänhet.
56. "Flunitrazepam utgår" [Flunitrazepam is discontinued]. Janusinfo (in Swedish). Stockholm.
57. "List of most commonly encountered drugs currently controlled under the misuse of drugs legislation". Gov.uk. August 8, 2022.
58. DEA
59. "Rohypnol". United States Drug Enforcement Administration. Retrieved October 18, 2020.

External links

• Molecule of the Month
• Statement on "Date Rape" Drugs by Associate Director for Domestic and International Drug Control, Office of Health Affairs, FDA, before Congress. Mar. 11, 1999.

• GABAA receptor positive allosteric modulators
• Glycine receptor antagonists
• Drugs developed by Hoffmann-La Roche
• Lactams
• Nitrobenzodiazepines
• 2-Fluorophenyl compounds
• Drug culture
• Drug-facilitated sexual assault